NOBLE Life Science Partners (NOBLE LSP), a division of Noble Capital Markets Inc. welcomes Camillo Ricordi, M.D. to its Scientific Advisory Board (SAB)

Kratos Defense & Security Solutions, Inc. (“Kratos”) (Nasdaq:KTOS), announced today the pricing of an underwritten offering of 14,000,000 shares of its common stock at a public offering price of $12.25 per share.

Noble Capital Markets, Inc., acting as the exclusive placement agent for subscribers residing in the United States,

NOBLE Capital Markets, a leading small-cap focused investment firm, announces the initiation of research coverage of Vectrus Inc.

Noble Capital Markets announced today that it has initiated research coverage on Marlin Gold Ltd. (TSXV: MLN.V, OTCQX: MLNGF). The report was issued by Senior Research Analyst, Michael Heim, CFA.

Noble Capital Markets announced today that it has initiated research coverage on AAR Corp. (AIR). The report was issued by Research Analyst, Benjamin Klieve, CFA.

Noble Capital Markets announced today that it has initiated research coverage on DLH Holdings Corp. (DLHC). The report was issued by Senior Research Analyst, Mark Jordan, CFA.

Noble Capital Markets announced today that it has initiated research coverage on ESSA Pharma Inc. (EPIX). The report was issued by Noble's Head of Biotechnology Research, Kumar Raja, PhD.

Noble Capital Markets announced today that it has initiated research coverage on Endeavour Silver Corp. (EXK). The report was issued by Senior Research Analyst, Michael Heim, CFA.

Noble Capital Markets announced today that it has initiated research coverage on Anavex Life Sciences Corp. (AVXL) The report was issued by Noble's Head of Biotechnology Research, Kumar Raja, PhD.

Noble Life Science Partners, a division of Noble Financial Capital Markets (Noble) announced today that Nathan Cali, formerly Noble’s specialty pharmaceuticals senior analyst, has moved to its investment banking department.

Noble Life Science Partners, a division of Noble Financial Capital Markets (Noble) announced today that Cynapsus Therapeutics, Inc. (Cynapsus – NASADQ;CYNA) will no longer attend its fourth consecutive Noble Investor Conference - NobleCon13 to be held at the Boca Raton Resort & Club, January 30-31, 2017 – as it has been acquired by Sunovion Pharmaceuticals, at a purchase price of $624 million USD ($820 million CND). Noble was the first to initiate equity research coverage on Cynapsus and has supported the company’s growth through three rounds of financing totaling in excess of $100 million USD.

Noble Financial Capital Markets (Noble) announced today that it plans to expand its media sector team of analysts and investment bankers following the success of the Media Finance & Investor Conference (MFIC) held in Las Vegas last month. The Conference is produced in partnership with the National Association of Broadcasters (NAB) and was the partnership’s third annual event.

Pelican Therapeutics announced today that it won a $15,245,222 million New Company Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT).

When an unprecedented five Triangle-based biotechnology companies went public in 2013 and 2014, the mood on Wall Street was ebullient.

Rahul Jasuja, PhD Managing Director, Biotechnology Research NOBLE Life Science Partners will be a panelist at the “Immuno-Oncology: An Expanding Frontier” discussion at the Business of Biotech Conference hosted by the Moffitt Cancer Center – March 18, 2016